JP2013535190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013535190A5 JP2013535190A5 JP2013519849A JP2013519849A JP2013535190A5 JP 2013535190 A5 JP2013535190 A5 JP 2013535190A5 JP 2013519849 A JP2013519849 A JP 2013519849A JP 2013519849 A JP2013519849 A JP 2013519849A JP 2013535190 A5 JP2013535190 A5 JP 2013535190A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cadherin
- humanized antibody
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100024155 Cadherin-11 Human genes 0.000 claims 12
- 108010000953 osteoblast cadherin Proteins 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000012659 Joint disease Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36469810P | 2010-07-15 | 2010-07-15 | |
| US61/364,698 | 2010-07-15 | ||
| PCT/US2011/044172 WO2012009631A1 (en) | 2010-07-15 | 2011-07-15 | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016023490A Division JP6223483B2 (ja) | 2010-07-15 | 2016-02-10 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013535190A JP2013535190A (ja) | 2013-09-12 |
| JP2013535190A5 true JP2013535190A5 (enExample) | 2014-08-07 |
| JP5886283B2 JP5886283B2 (ja) | 2016-03-16 |
Family
ID=44630044
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519849A Expired - Fee Related JP5886283B2 (ja) | 2010-07-15 | 2011-07-15 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
| JP2016023490A Expired - Fee Related JP6223483B2 (ja) | 2010-07-15 | 2016-02-10 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016023490A Expired - Fee Related JP6223483B2 (ja) | 2010-07-15 | 2016-02-10 | カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8940300B2 (enExample) |
| EP (2) | EP2593128B1 (enExample) |
| JP (2) | JP5886283B2 (enExample) |
| KR (1) | KR101695056B1 (enExample) |
| CN (2) | CN103153331B (enExample) |
| AU (1) | AU2011279044B2 (enExample) |
| BR (1) | BR112013001062A2 (enExample) |
| CA (1) | CA2805112A1 (enExample) |
| DK (1) | DK2593128T3 (enExample) |
| ES (1) | ES2665317T3 (enExample) |
| HR (1) | HRP20180563T1 (enExample) |
| HU (1) | HUE038000T2 (enExample) |
| IL (2) | IL224186A (enExample) |
| LT (1) | LT2593128T (enExample) |
| MX (1) | MX343376B (enExample) |
| NO (1) | NO2593128T3 (enExample) |
| PT (1) | PT2593128T (enExample) |
| RS (1) | RS57215B1 (enExample) |
| SG (1) | SG187097A1 (enExample) |
| SI (1) | SI2593128T1 (enExample) |
| WO (1) | WO2012009631A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009204467B2 (en) | 2008-01-11 | 2012-09-06 | Adheron Therapeutics, Inc. | Cadherin-11 ECl domain antagonists for treating inflammatory joint disorders |
| MX343376B (es) | 2010-07-15 | 2016-11-03 | Adheron Therapeutics Inc | Anticuerpos humanizados que tienen como objetivo el dominio ec1 de cadherina-11 y composiciones y metodos relacionados. |
| HRP20230065T1 (hr) | 2011-10-28 | 2023-03-03 | Prothena Biosciences Limited | Humanizirana protutijela koja prepoznaju alfa-sinuklein |
| SG11201404321YA (en) | 2012-01-27 | 2014-08-28 | Neotope Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
| US20150050240A1 (en) * | 2012-03-27 | 2015-02-19 | Novartis Ag | Treatment of fibrosis |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| JP2016515524A (ja) * | 2013-03-15 | 2016-05-30 | アッヴィ バイオテクノロジー リミテッド | 抗ｃｄ２５抗体およびそれらの使用 |
| US20150010538A1 (en) * | 2013-03-15 | 2015-01-08 | Abbvie Biotherapeutics Inc. | Anti-cd25 antibodies and their uses |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| WO2016100301A1 (en) * | 2014-12-15 | 2016-06-23 | The Brigham And Women's Hospital, Inc. | Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders |
| WO2017120557A1 (en) * | 2016-01-09 | 2017-07-13 | Arbele Limited | Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment |
| EP3830119B1 (en) * | 2018-08-01 | 2025-11-12 | Imcheck Therapeutics | Anti-btn3a antibodies and their use in treating cancer or infectious disorders |
| CN113072633B (zh) * | 2021-04-21 | 2022-11-15 | 湖北医药学院 | Cdh11截短型变体及其应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| EP0232262A4 (en) | 1985-08-15 | 1989-09-19 | Stauffer Chemical Co | TRYPTOPHANE GENERATING MICROORGANISM. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| ATE169030T1 (de) | 1990-06-28 | 1998-08-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5440021A (en) | 1991-03-29 | 1995-08-08 | Chuntharapai; Anan | Antibodies to human IL-8 type B receptor |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| JP3560252B2 (ja) * | 1992-08-28 | 2004-09-02 | アベンティス ファーマ株式会社 | 骨関連カドヘリン様タンパク質およびその製造法 |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| CU22584A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| US7481999B2 (en) | 1998-05-05 | 2009-01-27 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin-mediated function |
| US6472367B1 (en) | 1998-05-05 | 2002-10-29 | Adherex Technologies, Inc. | Compounds and methods for modulating OB-cadherin mediated cell adhesion |
| US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| WO1999057149A2 (en) * | 1998-05-05 | 1999-11-11 | Adherex Technologies, Inc. | Compounds and methods for modulating nonclassical cadherin-mediated functions |
| US6638911B1 (en) | 1998-05-05 | 2003-10-28 | Adherex Technologies Inc. | Compounds and methods for modulating desmosomal cadherin-mediated functions |
| PT1207905E (pt) | 1999-09-03 | 2010-12-07 | Brigham & Womens Hospital | Métodos e composições para o tratamento de doença inflamatória utilizando agentes moduladores da caderina-11 |
| US6787136B1 (en) | 1999-09-03 | 2004-09-07 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents |
| US20040110755A1 (en) | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
| AU2003298475A1 (en) | 2002-11-14 | 2004-06-18 | Adherex Technologies, Inc. | Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| WO2006089397A1 (en) | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Methods for treating arthritis using triheterocyclic compounds |
| AU2009204467B2 (en) | 2008-01-11 | 2012-09-06 | Adheron Therapeutics, Inc. | Cadherin-11 ECl domain antagonists for treating inflammatory joint disorders |
| WO2009101059A2 (en) * | 2008-02-11 | 2009-08-20 | Novartis Ag | Methods of using cadherin 11 (cdh11) antagonists |
| MX343376B (es) | 2010-07-15 | 2016-11-03 | Adheron Therapeutics Inc | Anticuerpos humanizados que tienen como objetivo el dominio ec1 de cadherina-11 y composiciones y metodos relacionados. |
-
2011
- 2011-07-15 MX MX2013000434A patent/MX343376B/es active IP Right Grant
- 2011-07-15 EP EP11741717.0A patent/EP2593128B1/en active Active
- 2011-07-15 CN CN201180042808.0A patent/CN103153331B/zh not_active Expired - Fee Related
- 2011-07-15 WO PCT/US2011/044172 patent/WO2012009631A1/en not_active Ceased
- 2011-07-15 BR BR112013001062A patent/BR112013001062A2/pt not_active Application Discontinuation
- 2011-07-15 HU HUE11741717A patent/HUE038000T2/hu unknown
- 2011-07-15 CN CN201710140463.1A patent/CN107090039A/zh active Pending
- 2011-07-15 SI SI201131461T patent/SI2593128T1/en unknown
- 2011-07-15 SG SG2013003454A patent/SG187097A1/en unknown
- 2011-07-15 AU AU2011279044A patent/AU2011279044B2/en not_active Ceased
- 2011-07-15 EP EP17203400.1A patent/EP3345925A3/en not_active Withdrawn
- 2011-07-15 PT PT117417170T patent/PT2593128T/pt unknown
- 2011-07-15 ES ES11741717.0T patent/ES2665317T3/es active Active
- 2011-07-15 US US13/810,018 patent/US8940300B2/en active Active
- 2011-07-15 LT LTEP11741717.0T patent/LT2593128T/lt unknown
- 2011-07-15 RS RS20180419A patent/RS57215B1/sr unknown
- 2011-07-15 HR HRP20180563TT patent/HRP20180563T1/hr unknown
- 2011-07-15 NO NO11741717A patent/NO2593128T3/no unknown
- 2011-07-15 CA CA2805112A patent/CA2805112A1/en not_active Abandoned
- 2011-07-15 KR KR1020137003804A patent/KR101695056B1/ko not_active Expired - Fee Related
- 2011-07-15 JP JP2013519849A patent/JP5886283B2/ja not_active Expired - Fee Related
- 2011-07-15 DK DK11741717.0T patent/DK2593128T3/en active
-
2013
- 2013-01-13 IL IL224186A patent/IL224186A/en active IP Right Grant
-
2015
- 2015-01-26 US US14/605,543 patent/US20150132305A1/en not_active Abandoned
-
2016
- 2016-01-26 IL IL243775A patent/IL243775A0/en unknown
- 2016-02-10 JP JP2016023490A patent/JP6223483B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126555A2 (es) | Anticuerpos de oncostatina m humana y métodos de uso | |
| JP2017052784A5 (enExample) | ||
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2013519364A5 (enExample) | ||
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| JP2014205674A5 (enExample) | ||
| WO2012009631A8 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods | |
| JP2014518883A5 (enExample) | ||
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2014503482A5 (enExample) | ||
| JP2010535012A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2021501744A5 (enExample) | ||
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
| JP2015500002A5 (enExample) | ||
| JP2012526542A5 (enExample) | ||
| AU2012325232A8 (en) | Stable multiple antigen-binding antibody | |
| AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
| JP2014510152A5 (enExample) | ||
| BR112012024710A8 (pt) | moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| CL2008002668A1 (es) | Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp. | |
| JP2014522236A5 (enExample) |